الفهرس 
Title : Significance of programmed death ligand-1 expression in ovarian carcinoma
CONTENTSOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Background: In Egypt, ovarian cancer is the third most common female cancer (4.7% of all female cancers). Epithelial ovarian cancer represents 82% of all primary malignant ovarian neoplasms and the most predominating histologic subtype is the serous type, accounting for 46% of the total malignant ovarian tumors. Recent developments in treatment modalities including surgery and chemotherapy regimens have achieved improvement in the short-term survival of patients. Nevertheless, the long term prognosis in advanced cases remains unsatisfactory requiring a new treatment strategy. Studies over the past decade have highlighted the strong influence of the immune system on the survival of patients with cancer. The programmed death 1 (PD-1) pathway has emerged as a powerful immune regulatory mechanism in cancer prompting intensive efforts to understand its physiological regulation, prognostic significance, and therapeutic potential. Aim of work: To investigate the relationship of immuno-histochemical expression of programmed death ligand-1(PD-L1) in serous ovarian carcinoma with patient outcome. Material and methods: Immunohistochemistry with p53was done and high grade serous carcinomas (diffuse or null pattern for p53) were subjected to PD-L1 staining (94 cases). CD4 and CD8 were carried to delineate the nature of tumor infiltrating lymphocytes (TILs) in the tumor microenviroment. Correlation with patient outcome was investigated